Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug combo shows promise for rare muscle disease in kids

NCT ID NCT05524311

First seen Nov 20, 2025 · Last updated May 20, 2026 · Updated 22 times

Summary

This study tested the drug baricitinib, given with steroids, in 16 children aged 3-18 with newly diagnosed juvenile dermatomyositis, a rare disease causing muscle weakness and skin rashes. The goal was to see if baricitinib works better than the usual treatment (methotrexate plus steroids) over 24 weeks. Researchers measured improvements in muscle strength, daily function, and quality of life using a standard scale (PRINTO 20).

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for JUVENILE DERMATOMYOSITIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Hopital Necker - Enfants malades : unité d'immuno-hématologie et rhumatologie

    Paris, France

  • Hôpital Brabois

    Nancy, France

  • Hôpital Femme Mère Enfant

    Bron, France

  • Hôpital Jeanne de Flandre

    Lille, France

  • Hôpital La Timone

    Marseille, France

  • Hôpital Necker - Enfants malades : service de dermatologie

    Paris, France

  • Hôpital Pellegrin

    Bordeaux, France

  • Hôpital Purpan

    Toulouse, France

  • Hôpital Robert Debré

    Paris, France

  • Hôpital Trousseau

    Paris, France

  • Hôpital Villeneuce

    Montpellier, France

  • Hôpital de Hautepierre

    Strasbourg, France

  • Hôpital du Kremlin-Bicêtre

    Paris, France

Conditions

Explore the condition pages connected to this study.